Introduction {#S0001}
============

A randomized controlled trial (RCT) represents the most rigorous study design for determining the efficacy of a medical treatment. Results derived from a well-designed RCT have high internal validity since effective randomization affords protection from the influence of known and unknown confounding factors between treatment groups. Blinding of patients, physicians, and outcome assessors in an RCT provides an additional safeguard from bias. Participants in a clinical trial may behave differently if made aware of their assigned treatment, which could affect their response to therapy, compliance with concomitant interventions, and the decision to remain in the trial.[@CIT0001] Such performance and detection biases may confound study outcomes and interfere with data interpretation.

Blinding is particularly challenging to implement in RCTs of surgical treatments where obvious differences in cosmesis, imaging results, physical function, and postoperative care may inadvertently allow patients to determine which treatment was received with high probability.[@CIT0002] Further, ethics committees sometimes prohibit blinding of patients who receive surgical implants in a clinical trial. Recently, a large RCT was conducted to evaluate the efficacy of lumbar discectomy with or without a bone-anchored annular closure device (ACD) in patients at high-risk of lumbar disc reherniation.[@CIT0003] Through 2 years of follow-up, implantation of the ACD following discectomy was shown to significantly lower the risk of symptomatic reherniation and reoperation compared to patients treated with lumbar discectomy only.[@CIT0004] In this trial, patient blinding was implemented only at sites where permitted by ethics committees. Therefore, it remains unclear to what extent, if any, patient blinding status among study sites influenced these results. The objective of this secondary analysis from an RCT was to compare 2-year clinical outcomes of blinded vs unblinded patients who were treated with lumbar discectomy and a bone-anchored ACD for prevention of lumbar disc reherniation.

Methods {#S0002}
=======

Trial Design {#S0002-S2001}
------------

This was a multicenter RCT of lumbar discectomy with or without implantation of a bone-anchored ACD for prevention of lumbar disc reherniation (ClinicalTrials.gov NCT01283438) in patients at high risk for recurrence due to a large annular defect size.[@CIT0005] The protocol was approved by regional ethics committees ([[Supplement Table 1](http://www.dovepress.com/get_supplementary_file.php?f=216980.docx)]{.ul}), all patients provided written informed consent before trial participation, and the study was conducted in accordance with the Declaration of Helsinki. The design[@CIT0003] and 2-year primary endpoint results[@CIT0004] of this trial have been reported previously. Patients enrolled at sites in The Netherlands were blinded to treatment allocation per guidelines set forth in a prospective protocol. Patients were not blinded to treatment at all other participating sites. This analysis focuses on the results from the trial that are relevant to addressing the question of whether patient blinding status may have influenced clinical outcomes in patients treated with a bone-anchored ACD.

Patients {#S0002-S2002}
--------

Patients who were eligible to participate in this trial presented with symptomatic, single-level lumbar disc herniation that persisted despite at least 6 weeks of conservative management. Lumbar disc herniation was identified using MRI. Additional study imaging included low-dose computed tomography at the index level and anteroposterior/lateral and flexion/extension x-rays. Clinical corroboration of imaging findings was obtained by a positive straight leg raise or femoral stretch test. Symptom severity thresholds for study inclusion were leg pain severity at least 40/100 and Oswestry Disability Index (ODI) at least 40/100. Patients who met these presurgical criteria were then scheduled for lumbar discectomy.

Procedure And Randomization {#S0002-S2003}
---------------------------

Patients were treated on an inpatient basis with limited lumbar microdiscectomy using an interlaminar transflaval approach as described by Spengler.[@CIT0006] Once the discectomy procedure was completed, an interoperative eligibility criterion was applied in which eligible patients had a large (4--6 mm height, 6--10 mm width) postsurgical defect in the annulus fibrosus. Eligible patients were then randomly allocated, 1:1, to receive lumbar discectomy with no additional treatment or lumbar discectomy followed by an implantation procedure which includes a bone-anchored ACD.

Follow-Up And Outcomes {#S0002-S2004}
----------------------

Patients returned for follow-up visits at 6 weeks, 3 months, 6 months, 1 year, and 2 years. Follow-up visits consisted of imaging (MRI, low-dose computed tomography at the index level, and anteroposterior/lateral and flexion/extension x-rays) and clinical evaluations. Key clinical outcomes were back pain severity, leg pain severity, ODI, symptomatic reherniation, reoperation at the treated lumbar level, and device- or procedure-related serious adverse events (AEs). Surgeons and clinical outcome assessors were not blinded to treatment allocation at any site. Safety oversight and AE adjudication were provided by an independent data safety monitoring board.

Propensity Score-Matching {#S0002-S2005}
-------------------------

We anticipated that blinded and unblinded patients in the ACD group may differ with respect to baseline characteristics. Using data from eight clinically relevant baseline covariates (age, sex, body mass index, current smoking status, back pain, leg pain, ODI, and treated level), we calculated propensity scores for each patient using binomial logistic regression. Propensity score-matching (1:1) was then performed using a nearest neighbor greedy match technique without replacement to adjust for covariate imbalances. The caliper width was set at 0.1 SDs of the logit of the propensity score.[@CIT0007] This technique matched each blinded patient to the unblinded patient with the closest propensity score provided the scores differed by no more than the caliper width.

Statistical Analysis {#S0002-S2006}
--------------------

We verified the performance of propensity score-matching by comparing the distribution of covariates between blinded and unblinded groups before and after adjustment using the absolute standardized difference statistic, which was calculated as the difference in means or proportions among groups divided by the pooled SD. Absolute standardized difference values of 0.1, 0.2, and 0.5 indicate negligible, small, and moderate group differences, respectively.[@CIT0008] Continuous variables were reported as mean±SD, and categorical variables were presented as counts (percentages). Comparison of baseline characteristics was carried out with independent samples *t*-test or Fisher's exact test in the unadjusted sample, and with dependent samples *t*-test or the McNemar test in the propensity score-matched sample. Patient-reported outcomes over a 2-year follow-up were compared with mixed-model ANOVA in which the baseline value served as a covariate. Time-to-event data were compared with log-rank tests and Cox proportional hazards regression, adjusted for paired samples among matched patients. Two-sided *P*-values of less than 0.05 were considered statistically significant. Statistical analyses were performed using Stata v14.2 (StataCorp).

Results {#S0003}
=======

Among 276 patients from 21 sites where bone-anchored ACD implantation was attempted, 272 patients received a device and represent the sample of interest in the current study. A total of 237 patients were unblinded (including 3 cases of accidental unblinding) and 35 patients from four sites were blinded to their treatment assignment until the 2-year follow-up visit was completed.

Comparing blinded and unblinded patients, mild-to-moderate baseline differences were identified for male sex, leg pain severity, and treated level as evidenced by absolute standardized difference values larger than 0.2. Patient outcomes in the unadjusted sample are provided in [[Supplement Table 2](http://www.dovepress.com/get_supplementary_file.php?f=216980.docx)]{.ul}. After propensity score-matching, patient characteristics between groups (35 blinded, 35 unblinded) were well balanced with negligible differences for all covariates except for a minor imbalance in the proportion of patients treated at L5/S1 (63% vs 74%; absolute standardized difference = 0.29, *P*=0.50). Comparisons of baseline patient characteristics in each group before and after propensity score-matching are provided in [Table 1](#T0001){ref-type="table"}.Table 1Baseline Patient Characteristics In Unadjusted And Propensity Score-Matched Samples^a^CharacteristicUnadjusted SamplePropensity Score-Matched SampleBlinded (n=35)Unblinded (n=237)ASD^b^*P*Blinded (n=35)Unblinded (n=35)ASD^b^*P*Age, years42±843±110.160.3742±840±110.200.40Male sex16 (46)138 (58)0.280.4716 (46)17 (49)0.06\>0.99Body mass index, kg/m[@CIT0002]26±426±40.100.5726±426±50.070.79Current smoker18 (51)105 (44)0.160.4718 (51)17 (49)0.06\>0.99Back pain severity60±3256±300.120.5260±3256±300.130.59Leg pain severity85±1180±160.37\<0.0185±1185±120.080.73Oswestry Disability Index57±1359±120.170.3557±1358±110.130.58Lumbosacral treated level22 (63)116 (49)0.310.1522 (63)26 (74)0.290.50[^1][^2]

Over 2 years of follow-up, implantation of the ACD following lumbar discectomy was shown to be safe, which effectively prevented reherniation in these high-risk patients. Further, no statistically significant differences in patient-reported outcomes were observed between blinded and unblinded patients treated with the ACD. Following treatment, back pain severity rapidly decreased, with a 33-point reduction in each group observed at the 6-week follow-up interval. At 2 years of follow-up, back pain severity compared to baseline decreased by 40 points in blinded patients and 37 points in unblinded patients (*P*=0.61) ([Figure 1](#F0001){ref-type="fig"}). Comparing blinded to unblinded patients, leg pain severity decreased by 73 points in each group at 6 weeks, and these improvements were maintained through 2 years (75 vs 75 points, *P*\>0.99) ([Figure 2](#F0002){ref-type="fig"}). Similar trends were observed for ODI during follow-up, with reductions of 47 and 43 points (*P*=0.19), respectively, over 2 years ([Figure 3](#F0003){ref-type="fig"}). The risks of symptomatic reherniation (5.7% vs 9.1%; *P*=0.59) and reoperation (8.6% vs 12.2%, *P*=0.62) over 2 years were comparably low. The risk of a serious AE attributable to the device or procedure was similar in blinded and unblinded patients (5.7% vs 8.9%, *P*=0.63) ([Table 2](#T0002){ref-type="table"}).Table 2Time-To-Event Outcomes Through 2 Years In Propensity Score-Matched SampleOutcomeBlinded^a^Unblinded^a^HR (95% CI)^b^*P*Symptomatic reherniation5.7% (3.9%)9.1% (5.0%)0.61 (0.10, 3.67)0.59Reoperation8.6% (4.7%)12.2% (5.7%)0.68 (0.15, 3.05)0.62Serious adverse event^c^5.7% (3.9%)8.9% (4.9%)0.64 (0.11, 3.85)0.63[^3][^4] Figure 1Change in back pain severity over 2 years in blinded vs unblinded propensity score-matched patients treated with annular closure device.**Notes:** Plotted values are mean change and 95% CI with covariate adjustment for baseline value. *P*=0.61 for difference between groups.Figure 2Change in leg pain severity over 2 years in blinded vs unblinded propensity score-matched patients treated with annular closure device.**Notes:** Plotted values are mean change and 95% CI with covariate adjustment for baseline value. *P*\>0.99 for difference between groups.Figure 3Change in ODI over 2 years in blinded vs unblinded propensity score-matched patients treated with annular closure device.**Notes:** Plotted values are mean change and 95% CI with covariate adjustment for baseline value. *P*=0.19 for difference between groups.**Abbreviation:** ODI, Oswestry Disability Index.

Discussion {#S0004}
==========

In this analysis of patients treated with lumbar discectomy and ACD implantation for prevention of lumbar disc reherniation, there were no clinically important or statistically significant differences in back pain, leg pain, ODI, symptomatic reherniation, reoperation, or serious AEs over 2 years of follow-up when comparing blinded vs unblinded patients. These results were robust since they were observed in the unmatched sample as well as in the propensity score-matched sample that accounted for differences in baseline group characteristics.

The current study is one of the largest RCTs in spine surgery where patient blinding status was applied uniformly at each site but differed among sites. This presented a unique opportunity to investigate whether patient blinding status influenced clinical outcomes within the same trial. We are unaware of other studies in spine surgery with this study design element since most research on the influence of blinding has drawn comparisons between different studies, not within the same study.[@CIT0009]--[@CIT0012] Each of these studies concluded that treatment benefits were superior in unblinded vs blinded patients. In the current study, we observed no such effect as clinically meaningful and comparable treatment benefits were derived regardless of blinding status. A likely explanation for this finding relates to the intended function of the ACD. That is, lumbar discectomy is used to treat the index lumbar disc herniation and is the sole reason for relief from sciatica symptoms. Implantation of the ACD is not intended to treat disc herniation and associated symptoms, but instead serves to reduce the risk of reherniation in patients at high-risk due to a large postsurgical annular defect.[@CIT0005] Therefore, expectation bias may have been inherently minimized in the current study since symptom improvement was expected from the lumbar discectomy surgery, which was provided to all patients. Further, the possibility that patient blinding status influenced reherniation and reoperation rates is unlikely since these outcomes were largely driven by objective imaging evidence of reherniation in combination with patient symptoms, physical examination findings, and diagnostic testing results. Ultimately, the results of the current study were not significantly influenced by patient blinding status.

The conclusions of this study were strengthened by using the largest known sample of patients treated with an ACD, utilization of propensity score-matching to control for differences in measured baseline patient characteristics between blinded and unblinded groups, and 2-year patient follow-up. There were also several limitations of this research that warrant further discussion. First, propensity score adjustment cannot account for unmeasured variables such as possible regional differences in health-care delivery practices. Such unmeasured variables may have influenced patient outcomes and, thus, are important sources of possible bias. Second, the blinded group included only 35 patients who were treated among four sites in the same country. A larger sample distributed across more sites in different regions would provide a more robust sample for identifying the impact of patient blinding. Third, surgeons and outcome assessors were not blinded in this study; therefore, the independent effect of these potential biases on patient outcomes is unclear. Finally, these results are not applicable to all patients undergoing lumbar discectomy, but only to approximately 30% of patients at high risk of reherniation due to a large postsurgical annular defect.[@CIT0005] The ACD is not indicated for use in patients with smaller defects due to the relatively low risk of reherniation.

Conclusion {#S0005}
==========

In patients treated with lumbar discectomy and bone-anchored ACD, there were no clinically important or statistically significant differences in back pain, leg pain, ODI, symptomatic reherniation, reoperation, or serious AEs over 2 years of follow-up when comparing patients who were blinded vs unblinded to their treatment assignment.
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[^1]: **Notes:** ^a^Values are mean±SD, or count (percentage); ^b^ASD values of 0.1, 0.2, and 0.5 indicate negligible, small, and moderate group differences, respectively.

[^2]: **Abbreviation:** ASD, absolute standardized difference.

[^3]: **Notes:** ^a^Values indicate cumulative event incidence (SE) over 2 years derived from Kaplan--Meier analysis; ^b^Values indicate HR and 95% CI derived from Cox proportional hazards regression; ^c^Adjudicated as related to the procedure or device.

[^4]: **Abbreviation:** SE, standard error.
